A complex, interdisciplinary approach is needed to appropriately address the physical changes and emotional impact that patients undergoing hemipelvectomy will face postoperatively.
The new oral drug LY2835219, an inhibitor of cyclin-dependent kinases 4 and 6, showed early promise as monotherapy for patients with metastatic breast cancer.
The investigational drug DEDN6525A, a new antibody-drug conjugate, was safe, tolerable, and showed hints of activity against three forms of melanoma: cutaneous, mucosal, and ocular.
Adjuvant chemotherapy for breast cancer is gerontogenic, defined as accelerating the pace of physiologic aging, a new study reported.
The presence of chronic inflammation in benign prostate tissue samples is associated with prostate cancer, especially high-grade disease, according to a study.
Use of statins is associated with a reduced risk of progression of localized renal cell carcinoma, according to research.
Cyramza (ramucirumab) has been approved by the U.S. Food and Drug Administration to treat cancer of the stomach.
Ann J. Brady, MSN, RN-BC
Jia Conway, DNP, FNP-BC, AOCNP, NP-C
Michele M. Farrington, BSN, RN, CPHON
Donald R. Fleming, MD
Arati Jairam-Thodla, MSN, CNP
Karen MacDonald, RN, BSN, CPON
Marlene McGuire, RN, MA, ANP-C
Kerstin L. McSteen, BSN, MSN, ACHPN, CNS-BC
Helen H. Miller, LCSW, ACSW
Maribel Pereiras, PharmD, BCPS, BCOP
Leah A. Scaramuzzo, MSN, RN-BC, AOCN
Lisa A. Thompson, PharmD, BCOP
Rosemarie A. Tucci, RN, MSN, AOCN
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|